SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending with community chatter focusing on the stock's recent upward momentum, driven by speculation around potential catalysts and technical factors. Some traders point to a possible gamma squeeze and overall market strength, while others express skepticism, citing valuation concerns and mixed fundamentals. The discussion includes debate on whether the rally is sustainable or if a pullback is imminent.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

GEMI is trending following its IPO, with the community actively discussing allocation strategies and potential volatility. Initial trading saw a halt, sparking debates about market manipulation and comparisons to other hyped IPOs. Bullish sentiment remains as traders speculate on the stock's potential, while others express concern over its balance sheet.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

Anticipation is building around aTyr Pharma as it approaches the topline Phase 3 data release for efzofitimod in pulmonary sarcoidosis, driving significant community discussion. While some traders are eyeing a potential pump and dump scenario, others are optimistic about the trial's outcome and future indications, highlighting strong institutional ownership and potential for a short squeeze. The community is closely monitoring for any data leaks and debating the influence of prominent figures on the stock's movement.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is experiencing a surge in community interest, potentially fueled by a recent tweet and anticipation of a "God candle." Discussions revolve around the stock's squeezability, the promise of future technologies, and the belief in nodules as a source of power. Some investors are closely monitoring technical indicators, while others await a headline catalyst.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential partnerships and integrations, particularly within the Solana ecosystem. Bullish sentiment is fueled by discussions around real-world asset (RWA) adoption and the anticipation of increased volume as more markets open.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer ($PFE) is trending due to reports suggesting the Trump administration may link COVID-19 vaccines to child deaths, sparking concerns about potential liabilities and renewed scrutiny of vaccine safety data. The community is debating the validity of the reports and the potential impact on vaccine manufacturers, while some investors see the dip as a buying opportunity for the high-dividend stock.  Others believe Pfizer is more than just a vaccine company and should be evaluated as a cancer treatment company.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is trending due to recent earnings and increased discussion around its potential in AI data center power, with community members highlighting its fast “contract-to-power” deployment. Some are expressing optimism for a continued rally, while others are debating the company's path to profitability and comparing it to sector peers like BE and PLUG. Discussion also includes potential catalysts such as new deals, partnerships, and broader adoption of clean energy initiatives.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to regulatory clearance for its acquisition of Oxford Ionics, sparking discussions about the company's future and potential catalysts such as the upcoming Quantum World Congress. Community perspectives are mixed, with some highlighting the acquisition's significance while others express concerns about revenue and valuation. The stock is also being compared to NVDA, with some seeing it as the next big thing in computing.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recently announced $20 million investment agreement, sparking significant volatility and a mixed sentiment among traders. The community is actively discussing the potential for a short squeeze and upcoming news related to a conference. Some traders express concerns about dilution and the stock's history, while others remain optimistic about its long-term potential, especially with news expected next week.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. is trending as traders anticipate the closing of its merger with Strive, potentially transforming it into a Bitcoin treasury company; high short interest and borrow fees add to the excitement, with the community debating the impact of potential dilution and the timing of news releases, as well as the possibility of a short squeeze. Despite some volatility, many investors express confidence in the long-term potential, urging others to hold firm.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Sonnet BioTherapeutics, Inc. (SONN) soared on Monday after the company entered a definitive business combination agreement with Rorschach I LLC to build a reserve of HYPE, the token of the Hyperliquid Layer-1 blockchain.<a href="https://stocktwits.com/symbol/SONN">SONN shares</a> were trading 82% higher on Monday afternoon at the time of writing.At the closing of the transaction, the newly-created entity is to be named Hyperliquid Strategies Inc. (HSI), which is expected to hold approximately 12.6 million HYPE tokens, representing $583 million in value shortly before agreement signing and gross cash invested of at least $305 million, for a total assumed closing value of $888 million.The gross cash proceeds of $305 million at closing will enable HSI to acquire significantly more HYPE, creating one of the top strategic reserves of the HYPE token, the company said.HSI is expected to remain listed on the Nasdaq under a new ticker symbol and become a public cryptocurrency treasury company upon the closing of the transaction.Sonnet will operate as a wholly-owned subsidiary of HSI and will continue focusing on existing assets and business lines, including the development of its investigational cancer drug SON-1010, while disposing of other assets.Bob Diamond, co-founder and CEO of Atlas Merchant Capital LLC, will be named Chairman of the Board, and David Schamis, CIO and Co-founder of Atlas, will be named Chief Executive Officer of HSI.It is expected that current owners of Rorschach and other new investors at closing will own approximately 98.8% of HSI, and the legacy stockholders of SONN will own the remaining approximately 1.2%.Raghu Rao, interim CEO of Sonnet, said that with the transaction, the company will be able to capitalize on the recent advancements around digital assets and equip Sonnet with funding to potentially realize the future value of its existing biotech assets.Sonnet will also raise an aggregate $5.5 million in a private placement as part of the agreement, which is expected to close on July 14.The business combination agreement is now subject to approval by Sonnet stockholders and other customary closing conditions. The closing of the business combination is expected to occur in the second half of this year.On Stocktwits, retail sentiment around Sonnet is unchanged within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_14_at_2_14_50_PM_png_b81036dcad.webp" alt="SONN's Sentiment Meter and Message Volume as of 2:15 p.m. ET on July 14, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>SONN's Sentiment Meter and Message Volume as of 2:15 p.m. ET on July 14, 2025 | Source: Stocktwits</figcaption></figure>SONN stock is up by 545% this year and by 32% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-ceo-transfers-portion-of-holdings-to-ex-wife-as-part-of-divorce-settlement/ch893xvR5nB">Rivian CEO Transfers Portion Of Holdings In EV Maker To Ex-Wife As Part Of Divorce Settlement</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Sonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays Exuberant

Shares of Sonnet BioTherapeutics, Inc. (SONN) soared on Monday after the company entered a definitive business combination agreement with Rorschach I LLC to build a reserve of HYPE

Equity

At the closing of the transaction, the newly created combined entity will be named Hyperliquid Strategies Inc., which is expected to hold approximately 12.6 million HYPE tokens.

Sonnet BioTherapeutics Advances SON-080 into Phase 2 Trials

Sonnet BioTherapeutics Holdings (SONN) just unveiled an update. Promising results from the Phase 1b trial of SON-080 for chemotherapy-induced perip...

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ('Sonnet' or the 'Company'), a biopharmaceutical company developing innovative targeted biologic...

Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective

Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON-080 was reviewed by the study's Data Safety Monitoring Board (DSMB)The adverse event profile and tolerability...

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today...

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offeringExtensive preclinical data on SON-1210 published in Frontiers in ImmunologyReceived approval...

BTIG Reaffirms Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)

BTIG analyst Kaveri Pohlman maintained a Buy rating on Sonnet BioTherapeutics Holdings (SONN Research Report) on January 5 and set a price target...

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.

SONN
Sonnet BioTherapeutics Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SONN News

SONN Sonnet BioTherapeutics Holdings Inc